Rapid Responses to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: A Randomized Controlled Trial-Reference-Cited by-同舟云学术

Rapid Responses to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: A Randomized Controlled Trial

Published:2016-06-28 Issue:6 Volume:214 Page:845-853
ISSN:0022-1899
Container-title:Journal of Infectious Diseases
language:en
Short-container-title:J Infect Dis.

Author:

Atmar Robert L.,Baehner Frank,Cramer Jakob P.,Song Eric,Borkowski Astrid,Mendelman Paul M.

Funder

Takeda Vaccines

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Link

http://academic.oup.com/jid/article-pdf/214/6/845/7940605/jiw259.pdf

Reference21 articles.

1. Winter Vomiting Disease

2. Foodborne Disease Burden Epidemiology Reference Group 2007–2015. WHO estimates of the global burden of foodborne diseases. http://www.who.int/foodsafety/publications/foodborne_disease/fergreport/en/. Accessed 22 December 2015.

3. High Level of Gastrointestinal Nosocomial Infections in the German Surveillance System, 2002–2008

4. Norovirus and Medically Attended Gastroenteritis in U.S. Children

5. Risk groups for clinical complications of norovirus infections: an outbreak investigation

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A narrative review of norovirus epidemiology, biology, and challenges to vaccine development;npj Vaccines;2024-05-29

2. Gastroenteritis viruses other than rotaviruses;Molecular Medical Microbiology;2024

3. Unraveling the interplay between norovirus infection, gut microbiota, and novel antiviral approaches: a comprehensive review;Frontiers in Microbiology;2023-07-06

4. Immune responses in healthy adults elicited by a bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvant;Frontiers in Immunology;2023-06-26

5. Immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age: A phase 2 randomized, double-blind trial;Human Vaccines & Immunotherapeutics;2023-01-02